Daniel A Llano1,2, Priya Devanarayan3, Viswanath Devanarayan4,5. 1. Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign. 2. Carle Neuroscience Institute, Urbana. 3. Souderton Area High School, Souderton. 4. Charles River Laboratories, Horsham, PA. 5. Department of Mathematics, Statistics and Computer Science, University of Illinois at Chicago, Chicago, IL.
Abstract
BACKGROUND: Previous work has suggested that the brain and cerebrospinal fluid (CSF) levels of a neural protein involved in synaptic transmission, VGF (a noninitialism), may be altered in mild cognitive impairment (MCI) and Alzheimer Disease (AD). The objective of the current work is to examine the potential of CSF levels of a peptide derived from VGF to predict conversion from MCI to AD. MATERIALS AND METHODS: Using multivariate analytical approaches, the performance of the conventional biomarkers (CSF Aβ1-42 and phosphorylated tau +/- hippocampal volume) was compared with the same biomarkers combined with CSF VGF peptide levels in a large publicly available data set from human subjects. RESULTS: It was observed that VGF peptides are lowered in CSF of patients with AD compared with controls and that combinations of CSF Aβ1-42 and phosphorylated tau, hippocampal volume, and VGF peptide levels outperformed conventional biomarkers alone (hazard ratio=2.2 vs. 3.9), for predicting MCI to AD conversion. CONCLUSIONS: CSF VGF enhances the ability of conventional biomarkers to predict MCI to AD conversion. Future work will be needed to determine the specificity of VGF for AD versus other neurodegenerative diseases.
BACKGROUND: Previous work has suggested that the brain and cerebrospinal fluid (CSF) levels of a neural protein involved in synaptic transmission, VGF (a noninitialism), may be altered in mild cognitive impairment (MCI) and Alzheimer Disease (AD). The objective of the current work is to examine the potential of CSF levels of a peptide derived from VGF to predict conversion from MCI to AD. MATERIALS AND METHODS: Using multivariate analytical approaches, the performance of the conventional biomarkers (CSF Aβ1-42 and phosphorylated tau +/- hippocampal volume) was compared with the same biomarkers combined with CSF VGF peptide levels in a large publicly available data set from human subjects. RESULTS: It was observed that VGF peptides are lowered in CSF of patients with AD compared with controls and that combinations of CSF Aβ1-42 and phosphorylated tau, hippocampal volume, and VGF peptide levels outperformed conventional biomarkers alone (hazard ratio=2.2 vs. 3.9), for predicting MCI to AD conversion. CONCLUSIONS: CSF VGF enhances the ability of conventional biomarkers to predict MCI to AD conversion. Future work will be needed to determine the specificity of VGF for AD versus other neurodegenerative diseases.
Authors: Satoshi Muraoka; Annina M DeLeo; Manveen K Sethi; Kayo Yukawa-Takamatsu; Zijian Yang; Jina Ko; John D Hogan; Zhi Ruan; Yang You; Yuzhi Wang; Maria Medalla; Seiko Ikezu; Mei Chen; Weiming Xia; Santhi Gorantla; Howard E Gendelman; David Issadore; Joseph Zaia; Tsuneya Ikezu Journal: Alzheimers Dement Date: 2020-04-17 Impact factor: 21.566
Authors: Inger van Steenoven; Barbara Noli; Cristina Cocco; Gian-Luca Ferri; Patrick Oeckl; Markus Otto; Marleen J A Koel-Simmelink; Claire Bridel; Wiesje M van der Flier; Afina W Lemstra; Charlotte E Teunissen Journal: Int J Mol Sci Date: 2019-09-20 Impact factor: 5.923